Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

Hussein A. Tawbi, Caroline Robert, Jan C. Brase, Daniel Gusenleitner, Eduard Gasal, James Garrett, Alexander Savchenko, Güllü Görgün, Keith T. Flaherty, Antoni Ribas, Reinhard Dummer, Dirk Schadendorf, Georgina V. Long, Paul D. Nathan, Paolo A. Ascierto

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)'. Together they form a unique fingerprint.

Medicine & Life Sciences